Thomas F. Dejgaard

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial

Thomas F. Dejgaard, Christian S. Frandsen, Tanja Sofie Hansen et al. · The Lancet Diabetes & Endocrinology · 2015 · 167 citations

Obesity, Metabolic Syndrome, Type 1 +6

Changes in insulin sensitivity precede changes in body composition during 14 days of step reduction combined with overfeeding in healthy young men

Sine H. Knudsen, Louise Hansen, Maria Pedersen et al. · Journal of Applied Physiology · 2012 · 113 citations

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study

Christian S. Frandsen, Thomas F. Dejgaard, Jens J. Holst et al. · Diabetes Care · 2015 · 99 citations

Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial

Thomas F. Dejgaard, Signe Schmidt, Christian S. Frandsen et al. · Diabetes Obesity and Metabolism · 2019 · 63 citations

Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial

Nicklas J. Johansen, Thomas F. Dejgaard, Asger Lund et al. · The Lancet Diabetes & Endocrinology · 2020 · 61 citations

Nutrition, Type 1, Short-acting Exenatide +9